Skip to main content

Together we are beating cancer

Donate now

Cancer News

Clinical trials

Showing 12 out of 312 results

In the final post in our series about the HOPON clinical trial, we hear from a patient who recently took part in the research, Gerard Dean. In the final post in our series about the HOPON clinical trial, we hear from a patient who recently took part in the research, Gerard Dean.

by Emma Smith | Analysis | 9 January 2015

9 January 2015

In the second installment of our series on the HOPON clinical trial we hear from the research nurses who help to run the trial in Liverpool. In the second installment of our series on the HOPON clinical trial we hear from the research nurses who help to run the trial in Liverpool.

by Emma Smith | Analysis | 8 January 2015

8 January 2015

In the first of a three-part series we hear from a doctor whose clinical trial was funded by Stand Up To Cancer in 2012. In the first of a three-part series we hear from a doctor whose clinical trial was funded by Stand Up To Cancer in 2012.

by Emma Smith | Analysis | 7 January 2015

7 January 2015

  • Science & Technology
  • Health & Medicine

The shape of all things – the year of crystallography

To mark the year of crystallography, we focus on an important scientific duo who used this powerful tool to help develop cancer drugs. To mark the year of crystallography, we focus on an important scientific duo who used this powerful tool to help develop cancer drugs.

by Kathy Weston | Analysis | 23 December 2014

23 December 2014

This entry is part 20 of 30 in the series Our milestones
%postcontent%

In the second part of this two-part series, we look at our work with industry, why it's important, and how we try to influence the way drugs get to patients. In the second part of this two-part series, we look at our work with industry, why it's important, and how we try to influence the way drugs get to patients.

by Emma Smith | Analysis | 17 December 2014

17 December 2014

This entry is part 2 of 2 in the series Dances with Pharma
%postcontent%
Drugs

In this first in a two-part series, we take a look at how cancer drugs get to patients, and at some of reasons behind the spiralling costs. In this first in a two-part series, we take a look at how cancer drugs get to patients, and at some of reasons behind the spiralling costs.

by Emma Smith | Analysis | 16 December 2014

16 December 2014

This entry is part 1 of 2 in the series Dances with Pharma
%postcontent%

We take a look at the latest data from a clinical trial testing a 'sponge on a string' as a new way to detect oesophageal cancer early. We take a look at the latest data from a clinical trial testing a 'sponge on a string' as a new way to detect oesophageal cancer early.

by Emily Howlett | Analysis | 2 December 2014

2 December 2014

Chest X-ray

November is lung cancer awareness month, so we've pulled together key information about the disease and what we’re doing to improve survival. November is lung cancer awareness month, so we've pulled together key information about the disease and what we’re doing to improve survival.

by Nick Peel | Analysis | 9 November 2014

9 November 2014

  • Science & Technology
  • Health & Medicine

NCRI 2014 conference summary - day 1

Here's our round up from day one of the NCRI cancer conference in Liverpool Here's our round up from day one of the NCRI cancer conference in Liverpool

by Henry Scowcroft | Analysis | 3 November 2014

3 November 2014

PARP and inhibitor

Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK? Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK?

by Kat Arney | Analysis | 24 October 2014

24 October 2014